Bernd Seizinger Buys 40,000 Shares of Oncolytics Biotech (NASDAQ:ONCY) Stock

Oncolytics Biotech Inc. (NASDAQ:ONCY) Director Bernd Seizinger bought 40,000 shares of Oncolytics Biotech stock in a transaction that occurred on Thursday, February 12th. The stock was bought at an average price of $0.85 per share, with a total value of $34,000.00. Following the completion of the acquisition, the director owned 566,991 shares in the company, valued at approximately $481,942.35. The trade was a 7.59% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Oncolytics Biotech Stock Down 2.2%

Shares of ONCY stock opened at $0.83 on Friday. Oncolytics Biotech Inc. has a 12 month low of $0.33 and a 12 month high of $1.51. The company has a market cap of $88.60 million, a PE ratio of -2.98 and a beta of 0.99. The business’s 50 day moving average is $0.98 and its two-hundred day moving average is $1.07.

Oncolytics Biotech (NASDAQ:ONCY) last posted its quarterly earnings data on Wednesday, November 12th. The company reported ($0.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.12) by $0.02. As a group, equities analysts expect that Oncolytics Biotech Inc. will post -0.28 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

ONCY has been the topic of several research analyst reports. Zacks Research raised Oncolytics Biotech from a “hold” rating to a “strong-buy” rating in a research report on Friday, October 17th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Oncolytics Biotech in a report on Monday, December 29th. Wall Street Zen downgraded Oncolytics Biotech from a “hold” rating to a “sell” rating in a research report on Saturday, November 15th. Finally, HC Wainwright lifted their price target on Oncolytics Biotech from $5.00 to $10.00 and gave the stock a “buy” rating in a research report on Monday, November 17th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $6.25.

Institutional Investors Weigh In On Oncolytics Biotech

Several hedge funds have recently made changes to their positions in ONCY. Citadel Advisors LLC bought a new position in Oncolytics Biotech during the third quarter valued at about $535,000. Tocqueville Asset Management L.P. bought a new stake in shares of Oncolytics Biotech in the 4th quarter worth approximately $63,000. CIBC Private Wealth Group LLC acquired a new stake in shares of Oncolytics Biotech during the 4th quarter worth approximately $44,000. Ground Swell Capital LLC acquired a new stake in shares of Oncolytics Biotech during the 4th quarter worth approximately $30,000. Finally, Seeds Investor LLC increased its position in shares of Oncolytics Biotech by 17.8% during the second quarter. Seeds Investor LLC now owns 223,767 shares of the company’s stock valued at $173,000 after purchasing an additional 33,826 shares during the period. Institutional investors own 6.82% of the company’s stock.

About Oncolytics Biotech

Oncolytics Biotech Inc (NASDAQ: ONCY) is a clinical-stage biotechnology company focused on the development of novel oncolytic viral therapies for the treatment of cancer. The company’s lead investigational agent, pelareorep (Reolysin), is a proprietary formulation of reovirus engineered to selectively infect and destroy tumor cells while stimulating a systemic antitumor immune response. Oncolytics leverages the natural biology of the virus to enhance the activity of standard‐of‐care treatments and immune checkpoint inhibitors.

Pelareorep has progressed into multiple advanced clinical trials, with combination studies conducted in metastatic breast cancer, non‐small cell lung cancer and head and neck cancers.